Kensey Nash touts TriActiv FX results
This article was originally published in The Gray Sheet
Executive Summary
The 3.2% major adverse cardiac event (MACE) rate seen in the firm's prospective ASPIRE registry "is the lowest recorded to date from a sizable multi-center study of the [saphenous vein graft] population, and is less than half of the next best data set widely quoted by the cardiology community," the company said March 7. The results also demonstrate a 2.2% incidence of heart attacks with the TriActiv FX embolic protection system. Kensey Nash will showcase the registry data at the American College of Cardiology meeting in Atlanta this week (1"The Gray Sheet" Feb. 6, 2006, p. 10)...
You may also be interested in...
Kensey Nash’s next-gen TriActiv
Firm prepares for upcoming launch of its TriActiv FX embolic protection system after announcing 510(k) clearance for the next-generation system July 12. Compelling results from the company's ASPIRE trial - in which use of TriActiv FX was associated with a comparatively low major adverse cardiac event rate of 3.2% - along with a new rapid exchange system and unique inflation device will help distinguish the balloon-based system from competing devices, Kensey Nash suggests (1"The Gray Sheet" March 13, 2006, In Brief)...
Kensey Nash Looks To Augment TriActiv Embolic Protection Offerings
Kensey Nash is counting on the next-generation TriActiv Fx and TriActiv ProGuard embolic protection systems to substantially strengthen its endovascular business
Philips Portfolio Includes ‘No Single Product That Does Not Use A Type Of AI,’ Says CEO And AI Thought Leader Roy Jakobs
Philips CEO Roy Jakobs talks to Medtech Insight about the medtech firm’s decade-long history of embedding AI into its products and what he expects from the newly released draft framework by the National Academy of Medicine, which he helped develop as co-chair of the Steering Committee.